Volume 7 Supplement 1

Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

Comprehensive analysis of the KSHV MiRNA targetome by Ago-HITS-CLIP

  • Irina Haecker1,
  • Lauren Gay1,
  • Alison Morse1,
  • Marty McCrory1,
  • Yajie Yang1,
  • Jianhong Hu1,
  • Lauren McIntyre1 and
  • Rolf Renne1Email author
Infectious Agents and Cancer20127(Suppl 1):O4

https://doi.org/10.1186/1750-9378-7-S1-O4

Published: 19 April 2012

The gamma-herpesvirus Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is the etiological agent of Kaposi’s Sarcoma (KS), Primary Effusion Lymphoma (PEL) and a subset of Multicentric Castleman’s Disease (MCD) in immunocompromised individuals. As all herpesviruses KSHV has a latent and a lytic life cycle. Malignant cells in KS, PEL, and MCD are latently infected with KSHV. Interestingly, the virus encodes 12 miRNA genes giving rise to 25 mature miRNAs that are predominantly expressed during latency, i.e. in malignant cells. This, together with the increasing evidence for the involvement of miRNAs in cancer, suggests a potential role for the KSHV miRNAs in viral tumorigenesis. However, to date, very little is known about the function of these viral miRNAs. To address the question we performed Ago-HITS-CLIP [1] using the anti-Ago antibody 2A8 [2] to isolate RISC complexes from KSHV-infected lymphoma cells (BCBL1, BC3). RNAs extracted from these complexes were analyzed by Illumina sequencing to identify viral and cellular miRNAs and their target genes. The search for canonical seed sequence matches (nt 2-7) of the KSHV miRNAs within the mRNA-derived sequencing tags revealed more than 1000 cellular targets. Gene ontology analysis revealed that KSHV miRNA targets are enriched in genes involved in apoptosis, lymphocyte activation, cell cycle regulation, and transcriptional control. Importantly, we reproducibly obtained clusters of reads on experimentally confirmed KSHV miRNA target sites in several known target genes (e.g. Bach1, BCLAF1, and THBS1). New target genes are in the process of experimental validation, with 4 confirmed targets so far: TP53INP1, TPD52, ANXA2, C/EBPB. Target analysis for non-canonical seeds as well as for cellular miRNAs is currently ongoing.

Authors’ Affiliations

(1)
Department of Molecular Genetics and Microbiology, University of Florida

References

  1. Chi SW, Zang JB, Mele A, Darnell RB: Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009, 460 (7254): 479-86.PubMed CentralPubMedGoogle Scholar
  2. Nelson PT, De Planell-Saguer M, Lamprinaki S, Kiriakidou M, Zhang P, O’Doherty U, Mourelatos Z: A novel monoclonal antibody against human Argonaute proteins reveals unexpected characteristics of miRNAs in human blood cells. RNA. 2007, 13 (10): 1787-92. 10.1261/rna.646007.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Haecker et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement